Home » March / April 2022 » The future of remote pharma GMP auditing
2022 | March / April 2022

The future of remote pharma GMP auditing

by cyb2025
A. Leckie
EMA
GMP
life science
pharma
quality assurance
Remote Audit

ALASDAIR LECKIE
Rephine, Stevenage, Hertfordshire, United Kingdom

ABSTRACT

The COVID-19 pandemic saw pharma industry auditing move increasingly online and in place of on-site visits, we became familiar with virtual checks and inspections. Some auditors now say that virtual auditing could become a permanent solution, but deeper analysis shows that clients are not in favour of this option, says Alasdair Leckie, Operations Manager at Rephine Ltd.

There was a time that pharma regulators would never have considered the idea of remote audits to verify the manufacturing and distribution standards of supply-chain partners, but two years of pandemic have forced the industry to adapt.

ABOUT THE AUTHOR

Alasdair Leckie is Operations Manager at Rephine Ltd, a firm of deeply experienced GMP auditors which proactively helps pharmaceutical companies around the world with their supply-chain quality assurance. Alasdair has been with Rephine for nine years and has a Bachelor’s Degree in Chinese and Economics from SOAS, University of London.

Latest issue

November /December 2025

View Issue

Archive

For an even more in-depth scientific analysis, consult the archive

Chemistry Today - Archive
Go to archive

Content from magazine

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores.
View all content

Most popular

@2026 - All Right Reserved.

Login